Market capitalization | $39.24m |
Enterprise Value | $790.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.79 |
P/S ratio (TTM) P/S ratio | 39.24 |
P/B ratio (TTM) P/B ratio | 2.61 |
Revenue growth (TTM) Revenue growth | 11,011.11% |
Revenue (TTM) Revenue | $1.00m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast vTv Therapeutics, Inc. Class A:
1 Analyst has issued a forecast vTv Therapeutics, Inc. Class A:
Sep '24 |
+/-
%
|
||
Revenue | 1 1 |
9,900%
9,900%
|
|
Gross Profit | 0.91 0.91 |
1,238%
1,238%
|
|
EBITDA | -24 -24 |
12%
12%
|
EBIT (Operating Income) EBIT | -24 -24 |
12%
12%
|
Net Profit | -18 -18 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
Head office | United States |
CEO | Paul Sekhri |
Employees | 16 |
Founded | 2015 |
Website | www.vtvtherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.